Table 3 Cross-cancer genetic correlations (rg) calculated via LD-score regression (LDSC) for all cancer pairs with P < 0.05.
From: Pan-cancer study detects genetic risk variants and shared genetic basis in two large cohorts
Cancer site 1 | Cancer site 2 | rg (95% CI) | P |
|---|---|---|---|
Bladder | Breast | 0.22 (0.04–0.41) | 0.017 |
Breast | Esophagus/stomach | 0.26 (0.07–0.44) | 0.0069 |
Colon | Rectum | 0.85 (0.52–1.00) | 5.33 × 10−7 |
Endometrium | Testis | −0.41 (−0.70 to −0.11) | 0.0064 |
Esophagus/stomach | Lung | 0.44 (0.15–0.74) | 0.0035 |
Esophagus/stomach | Melanoma | −0.27 (−0.53 to −0.01) | 0.038 |
Esophagus/stomach | Non-Hodgkin’s lymphoma | 0.40 (0.10–0.70) | 0.0089 |
Esophagus/stomach | Rectum | 0.32 (0.04–0.60) | 0.024 |
Lung | Melanoma | −0.28 (−0.47 to −0.08) | 0.0048 |
Melanoma | Testis | 0.23 (0.03–0.44) | 0.028 |
Non-Hodgkin’s lymphoma | Prostate | −0.21 (−0.37 to −0.05) | 0.012 |
Prostate | Thyroid | 0.23 (0.05–0.41) | 0.013 |
